Molecule News and Research

RSS

Talecris Biotherapeutics announces 2010 eALTA award recipients

Talecris Biotherapeutics GmbH announced yesterday the recipients of the 2010 European alpha1-antitrypsin Laurell's Training Awards (eALTA). The annual awards, sponsored by Talecris, provide two fellowships of 50,000 euros to young investigators whose research aims to enhance the understanding and treatment of alpha1-antitrypsin deficiency (AAT deficiency).

21 Sep 2010

NIH awards grant to discover drug for alcoholism

With the ultimate goal to discover a drug that one day treats alcoholism, a University of Houston (UH) pharmacy professor is working on pinpointing the mechanisms in the brain that respond to alcohol.

21 Sep 2010

Researchers discover HIV-1 resists AZT drug

Rutgers researchers have discovered how HIV-1, the virus that causes AIDS, resists AZT, a drug widely used to treat AIDS. The scientists, who report their findings in Nature Structural & Molecular Biology, believe their discovery helps researchers understand how important anti-AIDS treatments can fail and could help AIDS researchers develop more effective treatment for the disease.

20 Sep 2010

Improper biological clocks tend to develop diabetes, obesity: Research

Biologists have found that a key protein that regulates the biological clocks of mammals also regulates glucose production in the liver and that altering the levels of this protein can improve the health of diabetic mice.

20 Sep 2010

Penn study reveals structure of cell division's key molecule

On average, one hundred billion cells in the human body divide over the course of a day. Most of the time the body gets it right but sometimes, problems in cell replication can lead to abnormalities in chromosomes resulting in many types of disorders, from cancer to Down Syndrome.

18 Sep 2010

Researchers reveal Prozac reactions to increase serotonin level

The response time to antidepressants, such as Prozac, is around three weeks. The adaptation mechanisms of the neurons to antidepressants has, until now, remained enigmatic. In particular, the researchers have revealed, for the first time, a sequence of reactions caused by Prozac at the neuron level, which contributes to an increase in the amounts of serotonin, a chemical "messenger" essential to the brain, and deficient in depressive individuals.

17 Sep 2010

New anti-pathogenic drugs render MRSA harmless without killing bacteria

Menachem Shoham, PhD, associate professor and researcher in the department of biochemistry at the Case Western Reserve University School of Medicine, has identified new anti-pathogenic drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus (MRSA) harmless by preventing the production of toxins that cause disease.

17 Sep 2010

Researchers discover chronic stress accelerates breast cancer progression

Chronic stress acts as a sort of fertilizer that feeds breast cancer progression, significantly accelerating the spread of disease in animal models, researchers at UCLA's Jonsson Comprehensive Cancer Center have found.

17 Sep 2010

Wistar Institute scientists publish detailed report on structure, function of Cdc13 domain in protein

Scientists at The Wistar Institute have published the first detailed report on the structure and function of a crucial domain in the protein known as Cdc13, which sustains telomeres by clamping to DNA and recruiting replicating enzymes to the area.

16 Sep 2010

Researchers target specific molecule in brain to prevent relapses in cocaine addicts

People who have used cocaine run a great risk of becoming addicted, even after long drug-free periods. Now researchers at Linköping University and their colleagues can point to a specific molecule in the brain as a possible target for treatment to prevent relapses.

16 Sep 2010

ASG-5ME compound kills pancreatic cancer cells: Researchers

A new investigational drug designed to penetrate and attack pancreatic cancer cells has been administered to a patient for the first time ever at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

16 Sep 2010

Study finds GRK2 molecule promotes cell death after heart attack

A molecule known to be involved in progressive heart failure has now been shown to also lead to permanent damage after a heart attack, according to researchers at Thomas Jefferson University.

16 Sep 2010

K.U.Leuven enters license agreement with Pfizer to commercialize anti-HIV drugs

K.U.Leuven announced today that on July 29th, 2010 they entered into a license agreement with Pfizer. The license agreement grants Pfizer exclusive and sublicenseable worldwide rights to further develop and commercialise K.U.Leuven's compounds with a new mechanism of action for the potential treatment of individuals infected with HIV, the virus that causes AIDS.

16 Sep 2010

Researchers win $4.1M NIH grant to develop low-cost, ultra-fast DNA sequencing method

A team led by Boston University biomedical engineering researchers has won a $4.1 million, four-year grant from the National Institutes of Health to refine its nanoscale, low-cost, ultra-fast DNA sequencing method that could lead to individual genome sequencing for less than $1,000.

16 Sep 2010

Molecule in cells predicts success of radiotherapy in individual bladder cancer patients

CANCER RESEARCH UK scientists have identified a molecule in cells which could predict the success of radiotherapy to treat individual bladder cancer patients, reveals research published in Cancer Research1 today (Wednesday).

15 Sep 2010

Wintherix announces WX04554 molecule can cause bone healing

Wintherix, LLC, a privately held biotechnology company focusing on bone healing and regenerative medicine, today announced that WX04554, a potent small molecule activator of the Wnt pathway, has been designated as a lead drug for clinical development in bone healing and repair indications.

15 Sep 2010

microRNA 451 enhances treatment response in stomach cancer patients: Research

"The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer", explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.

15 Sep 2010

USF receives grant for studying ways to protect fetal brain from maternal infection

University of South Florida (USF) neuroscientists have been awarded a $400,000 federal grant to study ways of protecting the developing fetal brain from the damaging effects of maternal infections, a suspected cause for certain types of autism.

15 Sep 2010

TransPharma Medical completes ViaDerm-GLP1 agonist Phase 1a trial for type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of diabetes mellitus type II.

14 Sep 2010

Scientists study nanometer scale to develop artificial molecular machines

Molecular machines can be found everywhere in nature, for example, transporting proteins through cells and aiding metabolism. To develop artificial molecular machines, scientists need to understand the rules that govern mechanics at the molecular or nanometer scale (a nanometer is a billionth of a meter).

14 Sep 2010